The stock of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) is a huge mover today! About 204,770 shares traded hands. Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) has declined 36.32% since April 5, 2016 and is downtrending. It has underperformed by 38.28% the S&P500.
The move comes after 8 months positive chart setup for the $136.47M company. It was reported on Nov, 7 by Barchart.com. We have $9.81 PT which if reached, will make NASDAQ:NVIV worth $169.22 million more.
According to Zacks Investment Research, “InVivo Therapeutics Holdings Corp. operates as a medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company intends to offer three products, including a biocompatible polymer scaffolding device to treat acute wound SCI; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute SCI; and a biocompatible polymer scaffolding device seeded with autologous hNSCs to treat acute and chronic SCI. InVivo Therapeutics Holdings Corp. is based in Cambridge, Massachusetts.”
More notable recent Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) news were published by: Marketwatch.com which released: “InVivo Therapeutics started at buy with $23.25 stock price target at Ladenburg …” on April 25, 2011, also Businesswire.com with their article: “InVivo Therapeutics Announces Appointment of Jeffrey Hatfield to Board of …” published on November 02, 2016, Businesswire.com published: “InVivo Therapeutics Holdings Corp. Announces Pricing of Public Offering of …” on March 15, 2016. More interesting news about Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) were released by: Businesswire.com and their article: “InVivo Therapeutics Announces Allegheny General Hospital as New Site for …” published on November 03, 2016 as well as Businesswire.com‘s news article titled: “InVivo Therapeutics Announces Bioengineered Neural Trailsâ„¢ Program for …” with publication date: December 02, 2015.
NVIV Company Profile
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., incorporated on April 2, 2003, is a research and clinical-stage biomaterials and biotechnology company. The Firm is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. It is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Firm has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.